Sponsor

Hauptinformation

  • Handelsname:
  • Sponsor
  • Verwenden für:
  • Pflanzen
  • Art der Medizin:
  • Agrochemisch

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Sponsor
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Fungizid

Weitere Informationen

Status

  • Quelle:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Zulassungsnummer:
  • I-4884
  • Letzte Änderung:
  • 06-09-2017

Packungsbeilage

Produkt:

Handelsbezeichnung: Sponsor (Parallelimport)

Produktekategorie

Ausl. Bewilligungsinhaber

Eidg. Zulassungsnummer

Fungizid

Syngenta Crop Protection S.P.A.

I-4884

Packungsbeilagenummer

Herkunftsland

Ausl. Zulassungsnummer

4316

Italien

13926

Stoff(e)

Gehalt

Formulierungscode

Wirkstoff:

Difenoconazole

24.8 % 250 g/l

EC Emulsionskonzentrat

Anwendungen

A Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

W Reben

Echter Mehltau der Rebe

Rotbrenner

Schwarzfäule der Rebe

Konzentration: 0.0125 %

Anwendung: Bis spätestens Mitte

August.

1, 2, 3

Endivien und

Blattzichorien

Kopfsalate

Marssonina-Blattfleckenkrankheit

(Salate)

Aufwandmenge: 0.5 l/ha

Wartefrist: 3 Woche(n)

Gewächshaus:

Gurken

Gummistengelkrankheit [Didymella

bryoniae]

Konzentration: 0.05 %

Wartefrist: 3 Tage

G Karotten

Alternaria-Möhrenschwärze

Aufwandmenge: 0.5 l/ha

Wartefrist: 2 Woche(n)

Knoblauch

Lauch

Schalotten

Zwiebeln

Alternaria-Purpurfleckenkrankheit

Rost auf Zwiebel-Arten

Samtfleckenkrankheit der

Zwiebelgewächse

Aufwandmenge: 0.5 l/ha

Wartefrist: 2 Woche(n)

G Kohlarten

Blattfleckenpilze

Aufwandmenge: 0.5 l/ha

Wartefrist: 2 Woche(n)

A Kultur

Schaderreger/Wirkung

Dosierungshinweise

Auflagen

G Nüsslisalat

Echte Mehltaupilze auf Nüsslisalat

Aufwandmenge: 0.5 l/ha

Anwendung: Vor- oder unmittelbar

nach der Pflanzung spätestens im 4-

Blatt-Stadium.

G Petersilie

Alternaria spp.

Septoria-Blattfleckenkrankheit der

Petersilie

Aufwandmenge: 0.5 l/ha

Wartefrist: 3 Woche(n)

Anwendung: Bis 1 Woche nach

dem Schnitt.

G Rande

Cercospora- und Ramularia-

Blattfleckenkrankheiten

Aufwandmenge: 0.5 l/ha

Wartefrist: 2 Woche(n)

G Schnittlauch

Samtfleckenkrankheit der

Zwiebelgewächse

Aufwandmenge: 0.5 l/ha

Wartefrist: 2 Woche(n)

Anwendung: Bis 1 Woche nach

dem Schnitt.

G Sellerie

Septoria-Blattfleckenkrankheit des

Selleries

Aufwandmenge: 0.5 l/ha

Wartefrist: 2 Woche(n)

G Spargel

Blattschwärze der Spargel

Spargelrost

Aufwandmenge: 0.5 - 1 l/ha

Anwendung: Im Sommer.

G Tomaten

Alternaria-Dürrfleckenkrankheit

Echter Mehltau der Tomate

Septoria-Blattfleckenkrankheit der

Tomate/Aubergine

Konzentration: 0.05 %

Wartefrist: 3 Tage

Raps

Wurzelhals- und Stengelfäule

Aufwandmenge: 0.5 l/ha

Anwendung: Stadium 20-27

(BBCH).

Weizen

Braunrost

Echter Mehltau des Getreides

Gelbrost

Aufwandmenge: 0.5 l/ha

Anwendung: Stadium 32-61

(BBCH).

Zuckerrübe

Cercospora- und Ramularia-

Blattfleckenkrankheiten

Aufwandmenge: 0.5 l/ha

Auflagen und Bemerkungen:

Auch für die Luftapplikation.

Maximal 3 Behandlungen pro Jahr.

Gegen Rotbrenner in Tankmischung mit Folpet (80% WP), Konz. 0.1%.

Maximal 4 Behandlungen pro Jahr.

Maximal 1 Behandlung pro Kultur.

In der Regel nur 1 Behandlung bei Befallsbeginn durchführen.

Gefahrenkennzeichnungen:

Es gilt die Einstufung und Kennzeichnung der ausländischen Originaletikette.

Zusätzliche Schweizerische Gefahrenkennzeichnungen:

SP 1 Mittel und/oder dessen Behälter nicht in Gewässer gelangen lassen.

Im Zweifelsfall gelten einzig die Originaldokumente der Zulassung. Die Erwähnung eines Produktes,

Wirkstoffes oder einer Firma stellt keine Empfehlung dar und bedeutet nicht, dass sich das Produkt im

Verkauf befindet.

24-9-2018

FDA Announces Availability of Resources for Animal Drug Sponsors

FDA Announces Availability of Resources for Animal Drug Sponsors

The FDA is making available two pre-recorded webinars and a slide presentation to help drug sponsors understand recent changes to the submission process for new animal drug applications and related submissions. The changes take effect 10/1/2018.

FDA - U.S. Food and Drug Administration

7-8-2018

FDA’s Center for Veterinary Medicine Announces Second eSubmitter Webinar in Ongoing Series

FDA’s Center for Veterinary Medicine Announces Second eSubmitter Webinar in Ongoing Series

On August 22, 2018, FDA-CVM will host the second of a three-part webinar series on using eSubmitter, CVM’s electronic submission tool for the animal drug approval process. Sponsors must use eSubmitter to submit applications as of October 1, 2018.

FDA - U.S. Food and Drug Administration

28-6-2018

FDA Releases Guidance to Help Animal Drug Sponsors with Antimicrobial Animal Drug Sales and Distribution Reporting Requirements

FDA Releases Guidance to Help Animal Drug Sponsors with Antimicrobial Animal Drug Sales and Distribution Reporting Requirements

FDA is releasing Guidance for Industry #252. This small entity compliance guide is intended to help small businesses comply with the Antimicrobial Animal Drug Sales and Distribution final rule.

FDA - U.S. Food and Drug Administration

29-5-2018

Leitfaden für teilnehmende Sponsoren

Leitfaden für teilnehmende Sponsoren

Pilotprojekt - Bearbeitung von Anträgen klinischer Prüfungen nach Verordnung (EU) Nr. 536/2014: Leitfaden für teilnehmende Sponsoren

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

3-5-2018

Better conditions for clinical trials in Denmark

Better conditions for clinical trials in Denmark

The Danish government, the Danish People's Party and the Danish Social-Liberal Party have agreed to exempt commercial sponsors from all fees for phase I clinical trials of medicines. The government has previously decided – in connection with the Budget Bill 2018 – to remove the Danish Medicines Agency’s fees for non-commercial (research-initiated) clinical trials of medicines.

Danish Medicines Agency

16-8-2017

Testing the exchange of E2B files

Testing the exchange of E2B files

Testing the exchange of E2B ICSRs/SUSARs between the Danish Medicines Agency and companies/sponsors must be completed by Friday 29 September 2017.

Danish Medicines Agency

13-2-2017

New Q&A for clinical trial sponsors regarding contractual arrangements with vendors for electronic systems

New Q&A for clinical trial sponsors regarding contractual arrangements with vendors for electronic systems

The Good Clinical Practice (GCP) inspectors of the EU member states have published a new Q&A based on the pitfalls for sponsors to be aware of regarding contractual arrangements with vendors for electronic systems in connection with clinical trials.

Danish Medicines Agency

30-8-2016

Clinical trials

Clinical trials

Now it is mandatory for sponsors to post clinical trial results in the European Clinical trials Database.

IMA - Icelandic Medicines Agency

6-7-2015

Clinical trial authorisation applications

Clinical trial authorisation applications

In 2014, the Danish Health and Medicines Authority received 284 applications for authorisation of clinical trials of medicines in humans, which is a decline of 3% compared to 2013. Commercial sponsors applied for 162 trials and researchers for 122.

Danish Medicines Agency

27-8-2018

Discontinuing pre-market evaluation of Herbal Component Names: Frequently asked questions (FAQs)

Discontinuing pre-market evaluation of Herbal Component Names: Frequently asked questions (FAQs)

Frequently asked questions to inform sponsors about discontinuing the pre-market evaluation of HCNs

Therapeutic Goods Administration - Australia

19-7-2018

Regulatory and procedural guideline:  Post-orphan medicinal product designation procedures: guidance for sponsors to submit an application via the current existing submission process until 19 Sept 2018

Regulatory and procedural guideline: Post-orphan medicinal product designation procedures: guidance for sponsors to submit an application via the current existing submission process until 19 Sept 2018

The opinions on orphan designation are adopted by the Committee for Orphan Medicinal Products (COMP) at their monthly meetings at the European Medicines Agency (EMA).

Europe - EMA - European Medicines Agency

29-5-2018

Ensure that you have optimised your Class I medical device ARTG entries

Ensure that you have optimised your Class I medical device ARTG entries

Information sheet to assist sponsors to optimise their Class I ARTG

Therapeutic Goods Administration - Australia

24-5-2018

Black Triangle Scheme: Information for sponsors

Black Triangle Scheme: Information for sponsors

Black Triangle Scheme - information updated May 2018

Therapeutic Goods Administration - Australia

23-5-2018

Scientific guideline:  Draft guideline on the responsibilities of the sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with good clinical practice and good manufacturing practice, draft: consul

Scientific guideline: Draft guideline on the responsibilities of the sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with good clinical practice and good manufacturing practice, draft: consul

The guideline lays down the principles for the two-step release and shipping of the investigational medicinal products by the qualified person and the sponsor. The guideline also describes the areas of interface between the manufacturer and the sponsor and the required contractual agreements.

Europe - EMA - European Medicines Agency

15-5-2018

Medicine labels: Guidance on TGO 91 and TGO 92

Medicine labels: Guidance on TGO 91 and TGO 92

The guidance for medicine labels has been updated to improve clarity for sponsors. It also includes new best practice on latex labelling.

Therapeutic Goods Administration - Australia

8-5-2018

Child-resistant packaging requirements for medicines - Guidance on TGO 95

Child-resistant packaging requirements for medicines - Guidance on TGO 95

New guidance document published to assist medicine sponsors in meeting the requirements for child-resistant packaging (TGO 95)

Therapeutic Goods Administration - Australia

23-4-2018

Which clinical trial scheme should I choose?

Which clinical trial scheme should I choose?

New interactive tool for sponsors

Therapeutic Goods Administration - Australia